8/5/2008

The FDA announced that it will not let outside experts serve on an advisory panel if they or their immediate relatives have a financial stake of $50,000 or more in a drug or medical-device firm being reviewed. The restriction is part of the agency's new policies that address concerns about its independent advisers' industry relationships, including objectivity and conflicts of interest.

Full Story:
Hill, The

Related Summaries